CPW
NVS icon

Crestmont Private Wealth’s Novartis NVS Stock Holding History

Crestmont Private Wealth’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$299K Buy
1,957
+305
+18% +$46.8K 0.09% 82
2025
Q4 		$228K Buy
+1,652
New +$216K 0.07% 81

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Crestmont Private Wealth's NVS Position: Q1 2026 in Review

Crestmont Private Wealth increased its Novartis (NVS) stake by 18% in Q1 2026, buying an estimated $46.8K and bringing the position to 1,957 shares worth $299K. The position accounts for 0.09% of the portfolio, ranked #82.

Crestmont Private Wealth first reported a position in NVS in Q4 2025 and has held it in 2 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Crestmont Private Wealth held 1,957 shares of Novartis worth $299K as of Q1 2026.
  • Crestmont Private Wealth bought 305 Novartis shares in Q1 2026, an estimated $46.8K.
  • Novartis made up 0.09% of Crestmont Private Wealth's portfolio in Q1 2026, its #82 holding.
  • Crestmont Private Wealth first reported a position in Novartis in Q4 2025 and has held it in 2 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Crestmont Private Wealth's 13F filing for Q1 2026, filed 8 May 2026.